Bmy stock forecast 2025 in equity research updates

In equity research updates, BMY stock forecast 2025 reflects demand from immunology markets and strategic partnerships, a factor that may offset pricing pressures in mature therapeutics. Bristol-Myers Squibb Company (NYSE:BMY) is a New York-based pharmaceutical industry company. It is facing some challenges, but management is actively addressing them. Efforts are underway to reduce costs, with an aim to cut approximately $1.5 billion in expenses annually by the end of 2025. In addition, the company intends to maintain its focus on research and development (R&D) in oncology, targeting areas that management expects will yield the highest returns on investment, helping to drive growth while managing expenses. Add Quiver Quantitative to your preferred sources on Google Analysts note that the BMY stock forecast 2025 is partially reliant on successful Phase III trials, which could expand its revenue base by nearly $1.2B annually if approvals materialize.